Improving patient selection through tumor genomic recharacterization to overcome resistance to targeted therapy: commentary on the final analysis of the INSIGHT trial
AME Clinical Trials Review · 2023
DOI: 10.21037/actr-23-29 ↗Kurz gefasst
Fachartikel in der Zeitschrift AME Clinical Trials Review, 2023. Verfasst von Federica Pecci und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Pecci, F., Ricciuti, B., Alessi, J. V., Giglio, A. D., & Federico, A. D. (2023). Improving patient selection through tumor genomic recharacterization to overcome resistance to targeted therapy: commentary on the final analysis of the INSIGHT trial. AME Clinical Trials Review. https://doi.org/10.21037/actr-23-29
Vancouver
Pecci F, Ricciuti B, Alessi JV, Giglio AD, Federico AD. Improving patient selection through tumor genomic recharacterization to overcome resistance to targeted therapy: commentary on the final analysis of the INSIGHT trial. AME Clinical Trials Review. 2023. doi:10.21037/actr-23-29
BibTeX
@article{Pecci2023,
author = {Pecci, Federica and Ricciuti, Biagio and Alessi, Joao V. and Giglio, Andrea De and Federico, Alessandro Di},
title = {Improving patient selection through tumor genomic recharacterization to overcome resistance to targeted therapy: commentary on the final analysis of the INSIGHT trial},
journal = {AME Clinical Trials Review},
year = {2023},
doi = {10.21037/actr-23-29}
}
EUVIMED